The company is a Korea-based company mainly engaged in the synthetic drug development business. The Company is engaged in the development and sale of anti-inflammatory and anti-fibrotic agents, targeted anticancer drugs, immune anticancer drugs, metabolic cancer drugs, autoimmune diseases and targeted anticancer drugs, antiviral and other products. The company was incorporated on June 4, 2015 and its shares are listed on KONEX Exchange on July 27, 2022.
Headquarters
617, 54, Changeop-Ro, Sujeong-Gu
Seongnam; Gyeonggi;
Contact Details: Purchase the Future Medicine Co. Ltd. report to view the information.
Website: http://www.futuremedicine.co.kr/
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service